Literature DB >> 35835111

Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.

Chunyi Hu1, Dongchun Ni2, Ki Hyun Nam3, Sonali Majumdar4, Justin McLean4, Henning Stahlberg2, Michael P Terns4, Ailong Ke5.   

Abstract

Type I CRISPR-Cas systems typically rely on a two-step process to degrade DNA. First, an RNA-guided complex named Cascade identifies the complementary DNA target. The helicase-nuclease fusion enzyme Cas3 is then recruited in trans for processive DNA degradation. Contrary to this model, here, we show that type I-A Cascade and Cas3 function as an integral effector complex. We provide four cryoelectron microscopy (cryo-EM) snapshots of the Pyrococcus furiosus (Pfu) type I-A effector complex in different stages of DNA recognition and degradation. The HD nuclease of Cas3 is autoinhibited inside the effector complex. It is only allosterically activated upon full R-loop formation, when the entire targeted region has been validated by the RNA guide. The mechanistic insights inspired us to convert Pfu Cascade-Cas3 into a high-sensitivity, low-background, and temperature-activated nucleic acid detection tool. Moreover, Pfu CRISPR-Cas3 shows robust bi-directional deletion-editing activity in human cells, which could find usage in allele-specific inactivation of disease-causing mutations.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; Cas3; deletion; genome editing; nucleic acid detection; type I CRISPR-Cas

Mesh:

Substances:

Year:  2022        PMID: 35835111      PMCID: PMC9357151          DOI: 10.1016/j.molcel.2022.06.007

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   19.328


  64 in total

1.  Loop-mediated isothermal amplification of DNA.

Authors:  T Notomi; H Okayama; H Masubuchi; T Yonekawa; K Watanabe; N Amino; T Hase
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

2.  Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements.

Authors:  Francisco J M Mojica; César Díez-Villaseñor; Jesús García-Martínez; Elena Soria
Journal:  J Mol Evol       Date:  2005-02       Impact factor: 2.395

3.  CRISPR RNA-guided DNA cleavage by reconstituted Type I-A immune effector complexes.

Authors:  Sonali Majumdar; Michael P Terns
Journal:  Extremophiles       Date:  2018-10-03       Impact factor: 2.395

4.  In vitro reconstitution of an Escherichia coli RNA-guided immune system reveals unidirectional, ATP-dependent degradation of DNA target.

Authors:  Sabin Mulepati; Scott Bailey
Journal:  J Biol Chem       Date:  2013-06-11       Impact factor: 5.157

5.  Structures of the RNA-guided surveillance complex from a bacterial immune system.

Authors:  Blake Wiedenheft; Gabriel C Lander; Kaihong Zhou; Matthijs M Jore; Stan J J Brouns; John van der Oost; Jennifer A Doudna; Eva Nogales
Journal:  Nature       Date:  2011-09-21       Impact factor: 49.962

6.  Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression.

Authors:  Michelle L Luo; Adam S Mullis; Ryan T Leenay; Chase L Beisel
Journal:  Nucleic Acids Res       Date:  2014-10-17       Impact factor: 16.971

7.  Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.

Authors:  Yuxi Chen; Jiaqi Liu; Shengyao Zhi; Qi Zheng; Wenbin Ma; Junjiu Huang; Yizhi Liu; Dan Liu; Puping Liang; Zhou Songyang
Journal:  Nat Commun       Date:  2020-06-19       Impact factor: 14.919

8.  CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity.

Authors:  Janice S Chen; Enbo Ma; Lucas B Harrington; Maria Da Costa; Xinran Tian; Joel M Palefsky; Jennifer A Doudna
Journal:  Science       Date:  2018-02-15       Impact factor: 47.728

9.  Genome editing in plants using CRISPR type I-D nuclease.

Authors:  Keishi Osakabe; Naoki Wada; Tomoko Miyaji; Emi Murakami; Kazuya Marui; Risa Ueta; Ryosuke Hashimoto; Chihiro Abe-Hara; Bihe Kong; Kentaro Yano; Yuriko Osakabe
Journal:  Commun Biol       Date:  2020-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.